Lazard Asset Management’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.19M | Sell |
102,799
-7,547
| -7% | -$87.4K | ﹤0.01% | 1228 |
|
|
2025
Q1 | $963K | Sell |
110,346
-16,154
| -13% | -$141K | ﹤0.01% | 1231 |
|
|
2024
Q4 | $1.82M | Sell |
126,500
-22,552
| -15% | -$324K | ﹤0.01% | 919 |
|
|
2024
Q3 | $3.36M | Buy |
149,052
+80,953
| +119% | +$1.83M | ﹤0.01% | 732 |
|
|
2024
Q2 | $1.32M | Sell |
68,099
-6,441
| -9% | -$125K | ﹤0.01% | 920 |
|
|
2024
Q1 | $2.8M | Buy |
74,540
+13,972
| +23% | +$524K | ﹤0.01% | 788 |
|
|
2023
Q4 | $3.39M | Sell |
60,568
-1,743
| -3% | -$97.5K | ﹤0.01% | 762 |
|
|
2023
Q3 | $2.57M | Sell |
62,311
-37,141
| -37% | -$1.53M | ﹤0.01% | 828 |
|
|
2023
Q2 | $5.55M | Buy |
99,452
+838
| +0.8% | +$46.8K | 0.01% | 686 |
|
|
2023
Q1 | $5.5M | Sell |
98,614
-269
| -0.3% | -$15K | 0.01% | 708 |
|
|
2022
Q4 | $3.6M | Sell |
98,883
-34,585
| -26% | -$1.26M | 0.01% | 791 |
|
|
2022
Q3 | $3.8M | Buy |
133,468
+6,393
| +5% | +$182K | 0.01% | 761 |
|
|
2022
Q2 | $5.75M | Buy |
127,075
+57,291
| +82% | +$2.59M | 0.01% | 707 |
|
|
2022
Q1 | $5.31M | Buy |
69,784
+16,550
| +31% | +$1.26M | 0.01% | 745 |
|
|
2021
Q4 | $7.93M | Buy |
53,234
+27,425
| +106% | +$4.08M | 0.01% | 690 |
|
|
2021
Q3 | $3.76M | Buy |
25,809
+1,212
| +5% | +$176K | ﹤0.01% | 817 |
|
|
2021
Q2 | $4.82M | Buy |
24,597
+24,265
| +7,309% | +$4.75M | 0.01% | 732 |
|
|
2021
Q1 | $60K | Buy |
332
+16
| +5% | +$2.89K | ﹤0.01% | 1368 |
|
|
2020
Q4 | $44K | Buy |
+316
| New | +$44K | ﹤0.01% | 1426 |
|